Intersect ENT (XENT) Tops Q2 EPS by 5c; Guides FY16

Intersect ENT (NASDAQ: XENT) reported Q2 EPS of ($0.21), $0.05 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $19.3 million versus the consensus estimate of $18.83 million.

2016 Outlook

Intersect ENT expects full year revenue at the low end of the previous guidance range of $78-$80 million. The company is raising its outlook for gross margin to 82%-83%, versus previous guidance of 80%-81%. The company’s outlook for third quarter 2016 revenue is approximately $17.8 million. Intersect ENT is maintaining its outlook for operating expenses of approximately $92 million and continues to expect a net use of cash for the year of approximately $25 million (“net use of cash” is the difference between the anticipated balances of cash and cash equivalents plus short-term investments at December 31, 2016 and the actual balances at December 31, 2015).

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c